The efficacy of MPA was investigated on CD34 primary cells isolated from blood samples of CML patients responding to imatinib (patient 1) or resistant to imatinib and nilotinib (patient 2 to 4). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.